Immuno-positron emission tomography (immunoPET) is a paradigm-shifting molecular
imaging modality combining the superior targeting specificity of monoclonal antibody (mAb) …

Nuclear medicine is composed of two complementary areas, imaging and therapy. Positron
emission tomography (PET) and single-photon imaging, including single-photon emission …

Immuno-positron emission tomography (immunoPET) with 89Zr-labeled antibodies has
shown great potential in cancer imaging. It can provide important information about the …

Antibodies have clearly demonstrated their utility as therapeutics, providing highly selective
and effective drugs to treat diseases in oncology, hematology, cardiology, immunology and …

This continuing educational review provides an overview on radiometals used for PET.
General aspects of radiometal-based radiotracers are covered, and the most frequently …

Nuclear medicine is defined as the use of radionuclides for diagnostic and therapeutic
applications. The imaging modalities positron emission tomography (PET) and single …

Abstract Purpose All clinical 89 Zr-immuno-PET studies are currently performed with the
chelator desferrioxamine (DFO). This chelator provides hexadentate coordination to …

Purpose Almost all radiolabellings of antibodies with 89 Zr currently employ the hexadentate
chelator desferrioxamine (DFO). However, DFO can lead to unwanted uptake of 89 Zr in …

Zirconium-89 has an ideal half-life for use in antibody-based PET imaging; however, when
used with the chelator DFO, there is an accumulation of radioactivity in the bone, suggesting …

89Zr-based imaging agents hold great promise as novel radio-tracers in nuclear medicine.
However, insufficient stability of currently used radiometal complexes in vivo is a safety …